Raloxifene


- TRADE NAME: Evista (Lilly)
- INDICATIONS: Osteoporosis; reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk for invasive breast cancer
- CLASS: Selective estrogen receptor modulator (SERM)
- HALF-LIFE: 27.7 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
PREGNANCY CATEGORY: X
INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 09/19/2018
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations 
- Breast feeding
- Geriatric
- Pediatric